CO2023012322A2 - Inhibidores de vmat2 y métodos de uso - Google Patents

Inhibidores de vmat2 y métodos de uso

Info

Publication number
CO2023012322A2
CO2023012322A2 CONC2023/0012322A CO2023012322A CO2023012322A2 CO 2023012322 A2 CO2023012322 A2 CO 2023012322A2 CO 2023012322 A CO2023012322 A CO 2023012322A CO 2023012322 A2 CO2023012322 A2 CO 2023012322A2
Authority
CO
Colombia
Prior art keywords
methods
vmat2 inhibitors
vmat2
inhibitors
compositions
Prior art date
Application number
CONC2023/0012322A
Other languages
English (en)
Spanish (es)
Inventor
Nicole Harriott
Nicholas Pagano
Byron A Boon
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CO2023012322A2 publication Critical patent/CO2023012322A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2023/0012322A 2021-03-22 2023-09-18 Inhibidores de vmat2 y métodos de uso CO2023012322A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163164135P 2021-03-22 2021-03-22
PCT/US2022/021080 WO2022203984A1 (en) 2021-03-22 2022-03-21 Vmat2 inhibitors and methods of use

Publications (1)

Publication Number Publication Date
CO2023012322A2 true CO2023012322A2 (es) 2023-10-09

Family

ID=81325053

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0012322A CO2023012322A2 (es) 2021-03-22 2023-09-18 Inhibidores de vmat2 y métodos de uso

Country Status (33)

Country Link
US (3) US11718618B2 (https=)
EP (2) EP4606429A3 (https=)
JP (1) JP2024511053A (https=)
KR (1) KR20230160308A (https=)
CN (1) CN117062815A (https=)
AR (1) AR125188A1 (https=)
AU (1) AU2022241988A1 (https=)
BR (1) BR112023016273A2 (https=)
CA (1) CA3207452A1 (https=)
CL (1) CL2023002785A1 (https=)
CO (1) CO2023012322A2 (https=)
CR (1) CR20230448A (https=)
DK (1) DK4168409T3 (https=)
DO (1) DOP2023000197A (https=)
EC (1) ECSP23070370A (https=)
ES (1) ES3032498T3 (https=)
FI (1) FI4168409T3 (https=)
HR (1) HRP20250868T1 (https=)
HU (1) HUE072220T2 (https=)
IL (1) IL305054A (https=)
JO (1) JOP20230205A1 (https=)
LT (1) LT4168409T (https=)
MA (1) MA60072B1 (https=)
MD (1) MD4168409T2 (https=)
MX (1) MX2023010566A (https=)
PE (1) PE20240822A1 (https=)
PL (1) PL4168409T3 (https=)
PT (1) PT4168409T (https=)
RS (1) RS67052B1 (https=)
SI (1) SI4168409T1 (https=)
SM (1) SMT202500408T1 (https=)
TW (1) TW202304901A (https=)
WO (1) WO2022203984A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209005A (en) 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
CA2650904C (en) 2006-05-02 2015-07-07 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US7897769B2 (en) 2007-10-25 2011-03-01 General Electric Company Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
US7910738B2 (en) 2007-11-29 2011-03-22 General Electric Company Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US8013161B1 (en) 2007-12-07 2011-09-06 General Electric Company Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
US7919622B2 (en) 2007-12-07 2011-04-05 Kande Kankanamalage Dayarathna Amarasinghe Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
PT2836241T (pt) 2012-04-10 2019-05-30 Lantheus Medical Imaging Inc Métodos de síntese de radiofármacos
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US8946255B2 (en) 2012-12-28 2015-02-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. Vmat2のベンゾキノロン阻害剤
US20160031840A1 (en) 2013-03-15 2016-02-04 University Of Kentucky Research Foundation 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds
GB201313291D0 (en) 2013-07-25 2013-09-11 Ge Healthcare Ltd Imaging neurological disease
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3398602A1 (en) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US9714246B2 (en) 2015-02-06 2017-07-25 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
RS61645B1 (sr) * 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ,インコーポレイテッド (S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法
US11999676B2 (en) 2016-04-21 2024-06-04 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
US10668030B2 (en) 2016-04-21 2020-06-02 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
TW201906818A (zh) 2017-05-31 2019-02-16 美商511製藥公司 新穎氘取代之正子發射斷層掃描(pet)顯影劑及其藥理應用
SG11202004165UA (en) 2017-11-08 2020-06-29 Yuhua Li Esters of dihydrotetrabenazine
WO2020086765A1 (en) 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
US12565495B2 (en) 2019-08-12 2026-03-03 Luye Innomind Pharma Shijiazhuang Co., Ltd. VMAT2 inhibitor and preparation method therefor and application thereof
US20210087191A1 (en) 2020-12-04 2021-03-25 Dispersol Technologies, Llc SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法

Also Published As

Publication number Publication date
BR112023016273A2 (pt) 2023-10-03
PL4168409T3 (pl) 2025-09-01
SMT202500408T1 (it) 2025-11-10
LT4168409T (lt) 2025-06-25
PT4168409T (pt) 2025-06-12
DOP2023000197A (es) 2023-11-15
SI4168409T1 (sl) 2025-08-29
CL2023002785A1 (es) 2024-02-02
US11718618B2 (en) 2023-08-08
HRP20250868T1 (hr) 2025-09-26
AU2022241988A1 (en) 2023-10-12
CR20230448A (es) 2023-10-27
MX2023010566A (es) 2023-09-21
ECSP23070370A (es) 2023-10-31
EP4168409B1 (en) 2025-05-07
JOP20230205A1 (ar) 2023-09-04
IL305054A (en) 2023-10-01
MD4168409T2 (ro) 2025-09-30
PE20240822A1 (es) 2024-04-18
CA3207452A1 (en) 2022-09-29
US20250333413A1 (en) 2025-10-30
FI4168409T3 (fi) 2025-06-25
CN117062815A (zh) 2023-11-14
MA60072B1 (fr) 2025-07-31
JP2024511053A (ja) 2024-03-12
EP4606429A3 (en) 2025-12-03
US20240010647A1 (en) 2024-01-11
DK4168409T3 (da) 2025-06-02
WO2022203984A1 (en) 2022-09-29
TW202304901A (zh) 2023-02-01
KR20230160308A (ko) 2023-11-23
ES3032498T3 (en) 2025-07-21
HUE072220T2 (hu) 2025-11-28
EP4168409A1 (en) 2023-04-26
US20230159528A1 (en) 2023-05-25
RS67052B1 (sr) 2025-08-29
AR125188A1 (es) 2023-06-21
EP4606429A2 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
UY39526A (es) Inhibidores de kras g12d
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CL2022000447A1 (es) Inhibidores de kras g12d
CL2021003373A1 (es) Nuevos inhibidores de egfr
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
ECSP21081726A (es) Inhibidores de dihidroorotato deshidrogenasa
BR112022017727A2 (pt) Inibidores de eif4e e usos dos mesmos
MD4010330T2 (ro) Derivați ai chinolinei ca inhibitori ai protein kinazei
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
JOP20240157A1 (ar) مشتقات أزا إندول واستخدامها كمثبطات كيناز erk
CL2020002217A1 (es) Uso de alcoxipirazoles como inhibidores de la nitrificación
CL2023002785A1 (es) Inhibidores de vmat2 y métodos de uso.
CL2022003122S1 (es) Recipiente
CL2020002216A1 (es) Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificación
CL2023002783A1 (es) Compuestos para regular inmunidad entrenada y sus métodos de uso
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere
CL2022003123S1 (es) Recipiente
DK4214210T3 (da) Forbindelser og sammensætninger som sppl2a-inhibitorer
CO2021009344A2 (es) Un novedoso compuesto derivado de alulosa
CL2022003127S1 (es) Recipiente
CL2025001527A1 (es) Derivados de piridina como inhibidores de proteína cinasas
AR113349A1 (es) Aditivo para disminuir el punto de escurrimiento de inhibidores de parafina
AR124109A1 (es) Inhibidores de kras g12d